Sign In
Buy ITRM
$0.0300
+0 (+0%)
At Close: Jun 30, 2026
Iterum Therapeutics Reports Second Quarter 2025 Financial Results
07:00am, Tuesday, 05'th Aug 2025
- - Launch of ORLYNVAH TM Expected August 2025— - -Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeu
Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025
08:00am, Tuesday, 29'th Jul 2025
DUBLIN, Ireland and CHICAGO, July 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infect
Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 02'nd Jul 2025
DUBLIN and CHICAGO, July 02, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiot
Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH™ Launch and Commercial Growth
07:00am, Monday, 30'th Jun 2025
DUBLIN and CHICAGO, June 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum” or the “Company”), a company committed to delivering next generation oral and IV antibiot
Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence
07:00am, Wednesday, 25'th Jun 2025
9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Resistant to Three or More Classes of Antibiotics 9.2% of Patients in REASSURE's Primary Population had a Baseline Pathogen Re
Iterum Therapeutics Announces Partnership for Commercialization Services
07:00am, Wednesday, 11'th Jun 2025
U.S. Commercial Launch of ORLYNVAH TM by Q4 2025; First Oral Penem Available in the U.S. Management to host a conference call at 4:30 p.m. ET today DUBLIN and CHICAGO, June 11, 2025 (GLOBE NEWSWIRE) -
Iterum Therapeutics Announces Extension of Term of Promissory Note
07:00am, Monday, 19'th May 2025
DUBLIN and CHICAGO, May 19, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a company focused on delivering next generation oral and IV antibiotics
Iterum Therapeutics plc (ITRM) Q1 2025 Earnings Call Transcript
01:44pm, Tuesday, 13'th May 2025
Iterum Therapeutics plc (NASDAQ:ITRM ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - Chief Executive Officer Judy Ma
Iterum Therapeutics Reports First Quarter 2025 Financial Results
07:00am, Tuesday, 13'th May 2025
--Preparing for Potential Launch of ORLYNVAH TM by Q4 2025-- - -Extended Cash Runway into 2026-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, May 13, 2025 (GLOBE
Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025
07:00am, Tuesday, 06'th May 2025
DUBLIN, Ireland and CHICAGO, May 06, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Company), a company focused on delivering next generation oral and IV antibiotics to treat infecti
Iterum Therapeutics Announces Closing of $5 Million Registered Direct Offering of Ordinary Shares
04:30pm, Wednesday, 30'th Apr 2025
DUBLIN, Ireland and CHICAGO, April 30, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat i
Iterum Therapeutics Announces $5 Million Registered Direct Offering of Ordinary Shares
08:00am, Tuesday, 29'th Apr 2025
DUBLIN, Ireland and CHICAGO, April 29, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a company focused on delivering next generation oral and IV antibiotics to treat i
DUBLIN and CHICAGO, April 14, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by mul
Iterum Therapeutics plc (ITRM) Q4 2024 Earnings Call Transcript
10:20am, Friday, 07'th Feb 2025
Iterum Therapeutics plc (NASDAQ:ITRM ) Q4 2024 Earnings Conference Call February 7, 2025 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey Fishman - CEO Judy Matthews - CFO Con
Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
07:00am, Friday, 07'th Feb 2025
- -ORLYNVAH TM Approved by FDA in Q4 2024— - -Extended Cash Runway-- --Company to host conference call today at 8:30amET-- DUBLIN and CHICAGO, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Iterum Therapeutics p
